Related Experiment Video

Updated: Jan 30, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.4K

Interplay of long non-coding RNAs and TGF/SMAD signaling in different cancers

Ammad Ahmad Farooqi1, Rukset Attar2, Muhammad Zahid Qureshi3

  • 1Laboratory for Translational Oncology and Personalized Medicine, Rashid Latif Medical College, Lahore.

Cellular and Molecular Biology (Noisy-Le-Grand, France)
|January 24, 2019
PubMed

Insights

Long non-coding RNAs (LncRNAs) play a key role in regulating the TGF/SMAD signaling pathway, crucial for cancer development. Targeting these LncRNAs offers promising new therapeutic strategies for cancer treatment.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • RNA Biology

Background:

  • Deregulated signaling pathways are central to cancer development and progression.
  • Non-coding RNAs (ncRNAs) have significantly advanced our understanding of gene regulation.
  • The complexity of cancer is further elucidated by the discovery of diverse ncRNA classes.

Purpose of the Study:

  • To review the central role of long non-coding RNAs (LncRNAs) in modulating the Transforming Growth Factor/ SMAD (TGF/SMAD) signaling pathway.
  • To explore the therapeutic potential of targeting LncRNAs involved in TGF/SMAD signaling.

Main Methods:

  • Literature review focusing on LncRNAs and their interaction with the TGF/SMAD pathway.
  • Analysis of evidence supporting the regulatory role of specific LncRNAs (e.g., MALAT1, HOTAIR, ANRIL) in TGF/SMAD signaling.
  • Overview of current and emerging therapeutic strategies targeting LncRNAs.

Main Results:

  • LncRNAs play a significant, predominantly positive, role in the contextual regulation of TGF/SMAD signaling.
  • Specific LncRNAs are identified as key modulators, influencing intracellular signaling and transduction cascades.
  • Evidence suggests LncRNAs enhance the flexibility and efficiency of TGF/SMAD-mediated signaling.

Conclusions:

  • LncRNAs are vital components in the regulatory networks of TGF/SMAD signaling.
  • Targeting LncRNAs presents a promising avenue for novel cancer therapeutics.
  • Therapeutic strategies including short-interfering RNA (siRNA) and nanotechnological delivery systems are under investigation.
Keywords:
ANRIL.CancerHOTAIRLncRNAMALAT1SMADSignalingTGF

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.2K
Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System11:06

Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System

Published on: July 30, 2018

11.1K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.9K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.6K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.5K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.6K
piRNA - Piwi-interacting RNAs02:57

piRNA - Piwi-interacting RNAs

PIWI-interacting RNAs, or piRNAs, are the most abundant short non-coding RNAs. More than 20,000 genes have been found in humans that code for piRNAs while only 2000 genes have been found for miRNAs. piRNAs can act at the transcriptional and post-transcriptional levels and have a vital role in silencing transposable elements present in germ cells. They are also involved in epigenetic silencing and activation. Previously, they were thought to function only in germ cells but new evidence suggests...
7.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.8K